Related Experiment Videos
Endocrine response to pregnanolone.
1Department of Obstetrics and Gynecology, University Hospital of Umeå, Sweden.
Summary
Pregnanolone administration did not adversely affect the hypothalamus-pituitary-gonadal (HPG) axis in women, regardless of menstrual cycle phase or premenstrual syndrome (PMS) status. These findings suggest pregnanolone is safe for HPG axis function.
Area of Science:
- Neuroendocrinology
- Reproductive endocrinology
Background:
- Neurosteroid effects, such as pregnanolone, are well-documented in animal models but less understood in humans.
- The impact of pregnanolone on the human hypothalamus-pituitary-gonadal (HPG) axis requires further elucidation, particularly concerning its role throughout the menstrual cycle and in premenstrual syndrome (PMS).
Purpose of the Study:
- To investigate the endocrine effects of pregnanolone administration on the HPG axis in women.
- To compare these effects between women with and without PMS during different phases of the menstrual cycle.
Main Methods:
- Eight women with PMS and eight control women received intravenous pregnanolone or vehicle.
- Hormone levels (progesterone, estradiol, LH, FSH, prolactin) were measured during the mid-follicular and late luteal phases.
Main Results:
- Intravenous pregnanolone increased progesterone in the follicular phase and decreased it in the luteal phase.
- No significant changes were observed in estradiol, LH, FSH, or prolactin levels.
- No differences in pregnanolone's endocrine effects were noted between PMS patients and control subjects.
Conclusions:
- Moderate doses of pregnanolone do not appear to negatively impact the HPG axis.
- These effects are consistent across different menstrual cycle phases and in women with or without PMS.